Adoptive cell therapy (ACT) with retrovirally transduced T cells and TriVax vaccination shows promise in boosting antitumor immune responses by expanding specific T cell populations.
Stat5, a transcription factor, is crucial for T cell proliferation and differentiation, and the study investigates engineered CD8 T cells with active STAT5 in combination with TriVax.
Results demonstrate that CA-STAT5 enhances T cell expansion, functional capabilities, and reduces exhaustion, leading to a stronger antitumor effect in melanoma models by inhibiting the PD-1/PD-L1 pathway.
There are major gaps in understanding how immunotherapy affects the nervous system in children, mostly due to a lack of research focused on pediatric patients.
Identifying and grading the neurotoxic effects of immunotherapy in children is complicated by inconsistent terminology and the variation in treatment responses based on factors like disease type and therapy methods.
The review emphasizes the need for further research into the specific neurotoxic effects of various immunotherapy approaches in pediatric oncology, as well as the unique challenges presented by combining therapies.
Interim results from two phase 1 trials demonstrate progress in the use of chimeric antigen receptor (CAR) T cell therapy for recurrent glioblastoma (GBM).
Lecanemab, an amyloid-targeting immunotherapy for Alzheimer’s, shows promise but comes with potential risks for patients.
An interprofessional team at a medical center developed resources like patient handouts and documentation templates to aid in the infusion process of lecanemab.
The team plans to share these developed resources and processes with other healthcare settings to improve implementation and monitoring.